Journal of Antimicrobial Chemotherapy (1989) 23, 201-207
© 1989 The British Society for Antimicrobial Chemotherapy
research-article |
In-vitro activity of tigemonam, an oral monobactam, against Gram-negative rods, including variants in ß-lactamase-production
Department of Medical Microbiology, The London Hospital Medical College Turner Street, London E1 2AD, UK
Received 20 July 1988; accepted 18 November 1988
Tigemonam was compared in vitro with other orally active ß-lactams, aztreonam and ciprofloxacin against a selection of Gram-negative clinical isolates and laboratory-derived ß-lactamase-producing variants. Of the orally active ß-lactams, tigemonam was the most potent, with a spectrum of activity similar to that of aztreonam. This included stability to plasmid-mediated ß-lactamases and poor induction of chromosomal ß-lactamases. The susceptibility to Class I enzymes was only clinically significant for derepressed Enterobacter cloacae mutants. Tigemonam may have a valuable role in the management of infection caused by enterobacteria, particularly if bioavailability following oral administration is confirmed in human subjects.